日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Lymphoid enhancer-binding factor 1 (LEF1) immunostaining as a surrogate for β-catenin (CTNNB1) mutations.

淋巴增强子结合因子 1 (LEF1) 免疫染色作为 β-catenin (CTNNB1) 突变的替代指标。

Hewer Ekkehard, Fischer Pascal David, Vassella Erik, Knabben Laura, Imboden Sara, Mueller Michael D, Rau Tilman T, Dettmer Matthias S

Real-World Data on Institutional Implementation of Screening for Mismatch Repair Deficiency and Lynch Syndrome in Endometrial Cancer Patients

子宫内膜癌患者错配修复缺陷和林奇综合征筛查的机构实施情况的真实世界数据

Joder, Carmen; Gmür, Andrea; Solass, Wiebke; Christe, Lucine; Rabaglio, Manuela; Fluri, Muriel; Rau, Tilman T; Saner, Flurina A M; Knabben, Laura; Imboden, Sara; Mueller, Michael D; Siegenthaler, Franziska

Depot medroxyprogesterone acetate and breast cancer: a systematic review

醋酸甲羟孕酮缓释剂与乳腺癌:一项系统性综述

Zürcher, Aline; Knabben, Laura; von Gernler, Marc; Stute, Petra

Influence of the levonorgestrel-releasing intrauterine system on the risk of breast cancer: a systematic review

左炔诺孕酮宫内节育系统对乳腺癌风险的影响:系统评价

Zürcher, Aline; Knabben, Laura; Janka, Heidrun; Stute, Petra

Group B streptococcal colonization in elderly women

老年女性B族链球菌定植

Baldan, Rossella; Droz, Sara; Casanova, Carlo; Knabben, Laura; Huang, Dorothy J; Brülisauer, Christine; Kind, André B; Krause, Elke; Mauerer, Stefanie; Spellerberg, Barbara; Sendi, Parham

How the "control-fate continuum" helps explain the genetic testing decision-making process: a grounded theory study

“控制-命运连续体”如何帮助解释基因检测决策过程:一项扎根理论研究

Zimmermann, Bettina M; Shaw, David; Heinimann, Karl; Knabben, Laura; Elger, Bernice; Koné, Insa

Bone in the breast? Long term toxicity 21 years after interstitial brachytherapy as a boost

乳房骨骼?间质近距离放射治疗作为强化治疗21年后出现的长期毒性。

Imboden, Sara; Knabben, Laura; Mueller, Michael D; Günthert, Andreas R; Lössl, Kristina